Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000)

Diagnostic Microbiology and Infectious Disease

Volumn 43, Issue 2, 2002, Pages 157-162

  Gordon, Kelley A ^a   Beach, Mondell L ^a   Biedenbach, Douglas J ^a   Jones, Ronald N ^a   Rhomberg, Paul R ^a   Mutnick, Alan H ^b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEICOPLANIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; DILUTION; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; GEOGRAPHIC DISTRIBUTION; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPECIES DIFFERENCE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS MITIS; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; ASIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; POPULATION SURVEILLANCE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS;

EID: 0036094575     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00374-7     Document Type: Article

References (21)

1. Group B streptococci causing neonatal blood stream infection: Antimicrobial susceptibility and serotyping. Results from SENTRY centers in the Western Hemisphere
2. Streptococcus pyogenes collected in Torino (Northwest Italy) between 1983 and 1998: Survey of macrolide resistance and trend of genotype by RAPD
3. Surveillance of antimicrobial resistance: What, how and whither?
4. Epidemiology and prevention of group A streptococcal infections: Acute respiratory tract infections, skin infections, and their sequelae at the close of the twentieth century
5. Prevalence and mechanisms of macrolide resistance in invasive and non-invasive group B streptococcus isolates from Ontario, Canada
6. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada, and Latin America
7. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS284756
8. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
9. High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan
10. Antimicrobial susceptibility of blood culture isolates of viridans group streptococci: Relationship to a change in empirical antibiotic therapy in febrile neutropenia
11. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective
12. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998-1999) multicenter surveillance study in Spain
13. MLS resistance phenotypes and mechanisms in β-haemolytic group B, C, and G streptococcus isolates in La Rioja, Spain
14. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants
15. Streptococcus
16. Group B streptococcal disease: From trials and tribulations to triumph and trepidation
17. In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999
18. Clonal relationship between US and French serotype V group B streptococcus isolates
19. Phenotypic and genotypic characterization of macrolide-resistant group A streptocccus strains in the province of Quebec, Canada